SPC3042:: a proapoptotic survivin inhibitor

被引:73
作者
Hansen, Jens Bo [1 ]
Fisker, Niels [1 ]
Westergaard, Majken [1 ]
Kjaerulff, Lene Sonderby [1 ]
Hansen, Henrik Frydenlund [1 ]
Thrue, Charlotte Albaek [1 ]
Rosenbohm, Christoph [1 ]
Wissenbach, Margit [1 ]
Orum, Henrik [1 ]
Koch, Troels [1 ]
机构
[1] Santaris Pharma AS, Div Res, DK-2970 Horsholm, Denmark
关键词
D O I
10.1158/1535-7163.MCT-08-0161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ability to regulate the cellular homeostasis of a higher organism through tight control of apoptosis and cell division is crucial for life. Dysregulation of these mechanisms is often associated with cancerous phenotypes in cells. Optimal cancer therapy is a fine balance between effective cancer cell killing and at the same time minimizing, or avoiding, damage to the surrounding healthy tissue. To obtain this, it is necessary to identify and inhibit molecular targets on which the cancer cells are strongly dependent. Survivin represents such a target, and it has been published previously that peptide vaccines, the small-molecule YM155, and the antisense molecule LY2181308/ISIS23722, via different mechanisms, have been used as survivin inhibitors. In this article, a new potent antisense inhibitor of survivin, SPC3042, is presented, and the properties of SPC3042 are compared with the previously published antisense drug, LY2181308/ISIS23722. SPC3042 is a 16-mer locked nucleic acid (LNA) oligonucleotide and designed as a fully phosphorothiolated gapmer containing 7 LNA nucleotides in the flanks. The LNA nucleotides in SPC3042 provide nuclease stability and higher potency for survivin mRNA inhibition compared with earlier generations of antisense reagents. It is shown that the down-regulation of survivin with SPC3042 leads to cell cycle arrest, pronounced cellular apoptosis, and down-regulation of Bcl-2. It is also shown that SPC3042 is a sensitizer of prostate cancer cells to Taxol treatment in vitro and in vivo.
引用
收藏
页码:2736 / 2745
页数:10
相关论文
共 47 条
[1]   Expression and prognostic significance of survivin in de novo acute myeloid leukaemia [J].
Adida, C ;
Recher, C ;
Raffoux, E ;
Daniel, MT ;
Taksin, AL ;
Rousselot, P ;
Sigaux, F ;
Degos, L ;
Altieri, DC ;
Dombret, H .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :196-203
[2]   Survivin, versatile modulation of cell division and apoptosis in cancer [J].
Altieri, DC .
ONCOGENE, 2003, 22 (53) :8581-8589
[3]   Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade [J].
Altura, RA ;
Olshefski, RS ;
Jiang, Y ;
Boué, DR .
BRITISH JOURNAL OF CANCER, 2003, 89 (09) :1743-1749
[4]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[5]   Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting [J].
Ambrosini, G ;
Adida, C ;
Sirugo, G ;
Altieri, DC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (18) :11177-11182
[6]   Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma [J].
Ansell, SM ;
Arendt, BK ;
Grote, DM ;
Jelinek, DF ;
Novak, AJ ;
Wellik, LE ;
Remstein, ED ;
Bennett, CF ;
Fielding, A .
LEUKEMIA, 2004, 18 (03) :616-623
[7]   Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis [J].
Beltrami, E ;
Plescia, J ;
Wilkinson, JC ;
Duckett, CS ;
Altieri, DC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (03) :2077-2084
[8]   Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design [J].
Braasch, DA ;
Liu, YH ;
Corey, DR .
NUCLEIC ACIDS RESEARCH, 2002, 30 (23) :5160-5167
[9]   Targeting Survivin Expression Induces Cell Proliferation Defect and Subsequent Cell Death Involving Mitochondrial Pathway in Myeloid Leukemic Cell [J].
Carter, Bing Z. ;
Wang, Rui-Yu ;
Schober, Wendy D. ;
Milella, Michele ;
Chism, David ;
Andreeff, Michael .
CELL CYCLE, 2003, 2 (05) :488-493
[10]   Survivin is required for stable checkpoint activation in taxol-treated HeLa cells [J].
Carvalho, A ;
Carmena, M ;
Sambade, C ;
Earnshaw, WC ;
Wheatley, SP .
JOURNAL OF CELL SCIENCE, 2003, 116 (14) :2987-2998